On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to David Chaplin, United Kingdom, for 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol (combretastatin A4 phosphate) for the treatment of anaplastic thyroid cancer.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
The sponsorship was transferred to Diamond BioPharm Limited, United Kingdom, in January 2013.
The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.
The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.
This medicine is now known as fosbretabulin tromethamine.
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (fosbretabulin tromethamine)
|Disease / condition||
Treatment of anaplastic thyroid cancer
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.